Skip to content
Screener

OptimizeRx OPRX Q4 2025 Annual earnings

Reported March 5, 2026 · After market close

Revenue$32.2MBeat by $1.3M
EPS$0.51Beat by $0.28
Revenue estimate$30.9M
EPS estimate$0.23

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate$0.19

Financials

Q4 2025

Income statement

See full
Revenue$32.2M-0.2%
Gross profit$24.1M+9.4%
Operating income$8.6M—
Net income$5.0M+6,536%
EPS (diluted)$0.26—

Balance sheet

See full
Cash & equivalents$23.4M+74.6%
Total debt$26.1M-21.4%
Total equity$128.3M+9.7%
Total assets$176.9M+3.4%

Cash flow

See full
Operating cash flow$7.1M+3,480%
CapEx$11.0K-35.3%
Free cash flow$7.1M+3,810%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$228.53M+155%
Enterprise value$231.27M+112%
P/E44.5×—
P/S2.1×+0.5×

Profitability

See full
Gross margin67.3%+27.0pp
Operating margin10.7%—
Net margin4.7%+2.5pp
FCF margin17%+8.3pp

Returns & leverage

See full
Return on equity4.2%+2.3pp
Debt / equity0.2×-0.1×
Current ratio3×+0.2×

FAQ

When did OptimizeRx report Q4 2025 earnings?
OptimizeRx (OPRX) reported Q4 2025 earnings on March 5, 2026 after market close.
What were OptimizeRx's Q4 2025 revenue and EPS?
OptimizeRx reported revenue of $32.2M and eps of $0.51 for Q4 2025.
Did OptimizeRx beat estimates in Q4 2025?
Revenue beat the consensus estimate of $30.9M by $1.3M. EPS beat the consensus estimate of $0.23 by $0.28.
How did OptimizeRx's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.2% from $32.3M a year earlier and eps grew 70.0% from $0.30.
Where can I find OptimizeRx's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001448431-26-000002) and the 10-K periodic report (0001448431-26-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.